Table 4 Pharmacokinetic parameters using non-compartmental analysis
From: In vivo study of newly developed albumin-conjugated urate oxidase for gout treatment
Parameter | After the first injection | After the second injection | After the third injection | After the fourth injection | ||||
|---|---|---|---|---|---|---|---|---|
PAT101 (1 mg/kg) | Rasburicase (0.325 mg/kg) | PAT101 (1 mg/kg) | Rasburicase (0.325 mg/kg) | PAT101 (1 mg/kg) | Rasburicase (0.325 mg/kg) | PAT101 (1 mg/kg) | Rasburicase (0.325 mg/kg) | |
T1/2 (hr) | 59.94 ± 10.23 | 2.45 ± 0.34 | 45.63 ± 13.68 | 2.71 ± 0.64 | 38.12 ± 3.75 | 2.56 ± 0.94 | 44.28 ± 16.99 | 2.38 ± 0.46 |
Tmax (hr) | 0.50 ± 0.00 | 0.50 ± 0.00 | 0.50 ± 0.00 | 0.50 ± 0.00 | 0.50 ± 0.00 | 0.50 ± 0.00 | 0.50 ± 0.00 | 0.50 ± 0.00 |
Cmax (mU/mL) | 83.11 ± 13.51 | 65.60 ± 18.44 | 99.65 ± 10.20 | 68.47 ± 5.86 | 101.28 ± 10.17 | 88.20 ± 6.73 | 96.78 ± 12.64 | 96.78 ± 12.43 |
AUClast (hr*mU/mL) | 3167.12 ± 579.44 | 307.27 ± 86.70 | 3156.94 ± 203.78 | 211.76 ± 22.49 | 3467.72 ± 241.20 | 266.18 ± 39.36 | 3346.13 ± 908.90 | 274.83 ± 36.50 |
AUCall (hr*mU/mL) | 3167.12 ± 579.44 | 362.28 ± 100.81 | 3156.94 ± 203.78 | 264.44 ± 33.37 | 3467.72 ± 241.20 | 330.13 ± 75.26 | 3346.13 ± 908.90 | 332.11 ± 41.02 |
AUCinf (hr*mU/mL) | 3838.56 ± 688.02 | 324.51 ± 89.50 | 4112.70 ± 529.69 | 238.64 ± 31.18 | 4156.78 ± 349.05 | 300.61 ± 67.02 | 4330.31 ± 1591.65 | 300.03 ± 36.23 |
AUC%Extrap (%) | 17.30 ± 5.02 | 5.47 ± 0.94 | 22.35 ± 9.57 | 10.98 ± 4.28 | 16.46 ± 3.16 | 10.22 ± 7.46 | 19.68 ± 11.68 | 8.47 ± 3.40 |
Vz (mg/mU/mL) | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |
Cl (mg/hr*mU/mL) | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 |